STOCK TITAN

Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Heat Biologics (NASDAQ:HTBX) will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 am ET for 90 days. Heat Biologics is focused on developing first-in-class therapies to modulate the immune system, with multiple oncology candidates and a COVID-19 vaccine in development. Their gp96 platform aims to activate immune responses against cancer. For more information, visit Heat's investor relations page.

Positive
  • None.
Negative
  • None.

DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

A webcast of Heat's presentation will be available on-demand as of 6:00 am ET, Monday, January 11, 2021, and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of Heat Biologics' website at https://ir.heatbio.com/ir-calendar.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/623643/Heat-Biologics-to-Present-at-the-HC-Wainwright-Virtual-BioConnect-2021-Conference

FAQ

When will Heat Biologics present at the H.C. Wainwright BioConnect 2021 Conference?

Heat Biologics will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021.

What is the ticker symbol for Heat Biologics?

The ticker symbol for Heat Biologics is HTBX.

How can I access the webcast of Heat Biologics' presentation?

The webcast will be available on-demand starting January 11 at 6:00 am ET, accessible for 90 days on Heat's investor relations website.

What types of therapies is Heat Biologics developing?

Heat Biologics is developing first-in-class therapies targeting oncology and a COVID-19 vaccine.

What is the gp96 platform used by Heat Biologics?

The gp96 platform is designed to activate immune responses against cancer and pathogenic antigens.

HTBX

NYSE:HTBX

HTBX Rankings

HTBX Latest News

HTBX Stock Data

72.59M
24.29M
5.2%
10.76%
Biotechnology
Healthcare
Link
United States
Morrisville